-
Teva's Migraine Treatment Found Effective For Children As Young As 6
Thursday, July 18, 2024 - 12:06pm | 562Read More...Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced on Thursday topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17. The trial met its primary endpoint with Ajovy...
-
Vaporized Cannabis: A Promising Migraine Treatment, Suggests Study At American Headache Society Meeting
Monday, June 19, 2023 - 3:16pm | 508Read More...Medical marijuana, hemp and CBD have begun to receive increasingly serious consideration as viable medical alternatives, though research on cannabis’s impact on migraine headaches has been limited - that is until a group of headache experts all gathered in one spot. The 2023...
-
AbbVie's Migraine Treatment Drug Touts Encouraging Data In Preventive Treatment Setting
Thursday, March 10, 2022 - 12:44pm | 227Read More...AbbVie Inc (NYSE: ABBV) has reported data from the Phase 3 PROGRESS trial of atogepant (Qulipta) for the preventive treatment of chronic migraine in adults. The trial met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to...
-
Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial
Monday, December 6, 2021 - 1:14pm | 411Read More...Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its primary endpoints in a Phase 3 trial. The drug, zavegepant, a small-molecule CGRP receptor that can work as a spray...
-
FDA Clears Tonix Pharma's Human Trial With Intranasal Oxytocin For Migraine
Tuesday, November 23, 2021 - 9:40am | 266Read More...The FDA has signed off Tonix Pharmaceuticals Holding Corp's (NASDAQ: TNXP) Investigational New Drug (IND) Application to initiate Phase 2 study of TNX-1900 for migraine. TNX-1900 is intranasal potentiated oxytocin designed for the prevention of migraine headaches in...
-
Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M
Tuesday, November 9, 2021 - 11:49am | 365Read More...Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S. Rimegepant is commercialized as Nurtec ODT in the U.S. and is indicated for the acute treatment of migraine attacks with or...
-
FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie
Wednesday, September 29, 2021 - 8:37am | 227Read More...The FDA has approved AbbVie Inc's (NYSE: ABBV) Qulipta (atogepant) to prevent episodic migraines in adults. Qulipta is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist specifically developed for the preventive treatment of migraine. Qulipta will...
-
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
Tuesday, June 15, 2021 - 2:31pm | 272Read More...Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimegepant) orally disintegrating tablet (ODT) patients take every other...
-
Biohaven's Nurtec Wins FDA Approval As First Med to Prevent and Treat Migraine Attacks
Friday, May 28, 2021 - 8:00am | 244Read More...The FDA has approved Biohaven Pharmaceutical Holding Co Ltd’s (NYSE: BHVN) dissolvable, Nurtec ODT (rimegepant), for preventive treatment in people who experience episodic migraines or fewer than 15 days of headaches per month. The move makes Nurtec ODT the first oral anti-...
-
FDA Accepts AbbVie's Atogepant US Review Application For Migraine
Tuesday, March 30, 2021 - 9:30am | 179Read More...The FDA has accepted for review AbbVie Inc's (NYSE: ABBV) marketing application seeking approval for Atogepant for the preventive treatment of migraine in adults who meet the criteria for episodic migraine. The regulatory decision is expected in late Q3 2021. Atogepant is...
-
Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant
Monday, March 29, 2021 - 11:33am | 250Read More...Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has enrolled the first patient in a Phase 2/3 trial evaluating oral zavegepant for migraine's preventive treatment, triggering a milestone funding payment of $100 million. In August last year, Biohaven entered into a...
-
Satsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine
Monday, March 1, 2021 - 9:43am | 364Read More...Satsuma Pharmaceuticals Inc (NASDAQ: STSA) will conduct a new Phase 3 efficacy trial for STS101 (dihydroergotamine (DHE) nasal powder) as an acute treatment option for migraine. The study will start in mid-2021, with topline data expected in the second half of 2022. The new...
-
Teva's Preventive Migraine Treatment Approved By FDA
Monday, September 17, 2018 - 9:08am | 537Read More...Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA) — has struggled amid sagging sales of its blockbuster multiple sclerosis treatment Capaxone due to a generic launch in 2017 and its debt burden following the purchase of Allergan plc (NYSE: AGN)'s generic unit — has...
-
Cramer: Small-Cap Biotechs Are Reserved For Speculative Investors
Friday, July 14, 2017 - 1:18pm | 453Read More...Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) is clinical-stage biopharmaceutical company whose lead pivotal-stage product candidate, eptinezumab, is used for the treatment of migraines. The company is also one that ordinary investors should consider passing on, according to CNBC's Jim...
-
Alder Biopharma Surged 60% Following Phase 2 Results
Monday, March 28, 2016 - 11:15am | 272Read More...Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR), a clinical-stage biopharmaceutical company, surged higher by nearly 60 percent on Monday. Alder Biopharmaceuticals announced earlier in the morning positive top-line data from 2 clinical trials which studied its ALD403 product, an antibody...
